(-0.02%) 5 307.00 points
(0.03%) 40 156 points
(-0.03%) 18 499 points
(1.62%) $82.67
(0.12%) $1.720
(0.91%) $2 232.80
(-0.18%) $24.71
(0.44%) $913.70
(0.36%) $0.927
(0.60%) $10.83
(0.12%) $0.792
(-0.09%) $92.36
@ $1.418
Issued: 14 Feb 2024 @ 15:43
Return: 4.37%
Previous signal: Feb 13 - 12:41
Previous signal:
Return: 12.54 %
Live Chart Being Loaded With Signals
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases...
Stats | |
---|---|
Today's Volume | 1.28M |
Average Volume | 1.76M |
Market Cap | 170.30M |
EPS | $0 ( 2024-02-29 ) |
Next earnings date | ( $-0.330 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.180 |
ATR14 | $0.00600 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Paulson Richard A. | Sell | 3 573 | Common Stock |
2024-02-29 | Rangwala Reshma | Sell | 15 667 | Common |
2024-03-01 | Rangwala Reshma | Sell | 5 969 | Common |
2024-02-29 | Poulton Stuart | Sell | 16 311 | Common |
2024-03-01 | Poulton Stuart | Sell | 6 155 | Common |
INSIDER POWER |
---|
70.40 |
Last 99 transactions |
Buy: 2 857 011 | Sell: 548 860 |
Volume Correlation
Karyopharm Therapeutics Correlation
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Karyopharm Therapeutics Correlation - Currency/Commodity
Karyopharm Therapeutics Financials
Annual | 2023 |
Revenue: | $146.03M |
Gross Profit: | $140.56M (96.25 %) |
EPS: | $-1.250 |
Q4 | 2023 |
Revenue: | $33.75M |
Gross Profit: | $32.18M (95.37 %) |
EPS: | $-0.360 |
Q3 | 2023 |
Revenue: | $36.01M |
Gross Profit: | $35.10M (97.47 %) |
EPS: | $-0.300 |
Q2 | 2023 |
Revenue: | $37.58M |
Gross Profit: | $36.39M (96.82 %) |
EPS: | $-0.290 |
Financial Reports:
No articles found.
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators